//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы


Herr H.W. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001;19:89. https://www.ncbi.nlm.nih.gov/pubmed/11134199.

Shelley M.D. et al. Surgery versus radiotherapy for muscle invasive bladder voncancer. Cochrane Database Syst Rev. 2002:Cd002079. https://www.ncbi.nlm.nih.gov/pubmed/11869621.

Kachnic L.A. et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997;15:1022. https://www.ncbi.nlm.nih.gov/pubmed/9060542.

Sternberg C.N. et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer. 2003;97:1644. https://www.ncbi.nlm.nih.gov/pubmed/12655521.

Svatek R.S. et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010;16:4461. https://www.ncbi.nlm.nih.gov/pubmed/20651056.

Rosenberg J.E. et al. Update on chemotherapy for advanced bladder cancer. J Urol. 2005;174:14. https://www.ncbi.nlm.nih.gov/pubmed/15947569442.

Galsky M.D. et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29:2432. https://www.ncbi.nlm.nih.gov/pubmed/21555688.

Bellmunt J. et al. New therapeutic challenges in advanced bladder cancer. Semin Oncol. 2012;39:598. https://www.ncbi.nlm.nih.gov/pubmed/23040256.

Von der Maase H. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068. https://www.ncbi.nlm.nih.gov/pubmed/11001674.

Galsky M.D. et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23:406. https://www.ncbi.nlm.nih.gov/pubmed/21543626.

//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы


Meluch A.A. et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001;19:3018. https://www.ncbi.nlm.nih.gov/pubmed/11408496.

Sternberg C.N. et al. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol. 2003;46 Suppl:S105. https://www.ncbi.nlm.nih.gov/pubmed/12850531.

Bellmunt J. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454. https://www.ncbi.nlm.nih.gov/pubmed/19687335.

Powles T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558. https://www.ncbi.nlm.nih.gov/pubmed/25428503.

Zaghloul M.S. et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010;15:382. https://www.ncbi.nlm.nih.gov/pubmed/20354750.

Henry D.H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125. https://www.ncbi.nlm.nih.gov/pubmed/21343556.

Giannarini G. et al. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol. 2010;58:486. https://www.ncbi.nlm.nih.gov/pubmed/20541311.

Donat S.M. Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective? World J Urol. 2006;24:557. https://www.ncbi.nlm.nih.gov/pubmed/17009050.

Vrooman O.P. et al. Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. Curr Opin Urol. 2010;20:437. https://www.ncbi.nlm.nih.gov/pubmed/20657286.